Publications
- Ocrelizumab, clinical activity and progression - long - term data2019 | Faculty of Medicine in Hradec Králové
- Multiple sclerosis - escalation therapies and evidence-based medicine2017 | Faculty of Medicine in Hradec Králové
- Dimethyl fumarate and escalation therapy2017 | Faculty of Medicine in Hradec Králové
- Role of T and B cells in pathogenesis of multiple sclerosis2016 | Faculty of Medicine in Hradec Králové
- Escalation therapy in multiple sclerosis2016 | Faculty of Medicine in Hradec Králové
- Glatiramer acetate and three case reports2016 | Faculty of Medicine in Hradec Králové
- Indicators of clinical activity in multiple sclerosis and their influence treatment2014 | Faculty of Medicine in Hradec Králové
- Does initial high efficacy therapy in multiple sclerosis surpass escalation treatment strategy? A comparison of patients with relapsing-remitting multiple sclerosis in the Czech and Swedish national multiple sclerosis registries2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- The Czech National MS Registry (ReMuS): Data trends in multiple sclerosis patients whose first disease-modifying therapies were initiated from 2013 to 20212023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- The Benefits and Risks of Switching from Fingolimod to Siponimod for the Treatment of Relapsing-Remitting and Secondary Progressive Multiple Sclerosis2023 | Faculty of Medicine in Hradec Králové, First Faculty of Medicine, Second Faculty of Medicine
Loading network view...